In vivo sodium iodide symporter gene therapy of prostate cancer

C. Spitzweg, A. B. Dietz, M. K. O'Connor, E. R. Bergert, D. J. Tindall, C. Y.F. Young, J. C. Morris

Research output: Contribution to journalArticlepeer-review

149 Scopus citations


Radioiodine therapy, the most effective form of systemic radiotherapy available, is currently useful only for thyroid cancer because of thyroid-specific expression of the sodium iodide symporter (NIS). Here we explore the efficacy of a novel form of gene therapy using adenovirus-mediated in vivo NIS gene transfer followed by 131I administration for treatment of prostate cancer. Prostate cancer xenografts in nude mice injected with an adenovirus carrying the NIS gene linked to the cytomegalovirus (CMV) promoter revealed highly active uptake of radioiodine. Following administration of 3 mCi of 131I, we observed an average tumor volume reduction of 84 ± 12%. These results show for the first time that in vivo NIS gene delivery into non-thyroidal tumors is capable of inducing accumulation of therapeutically effective radioiodine doses and might therefore represent an effective and potentially curative therapy for prostate cancer.

Original languageEnglish (US)
Pages (from-to)1524-1531
Number of pages8
JournalGene Therapy
Issue number20
StatePublished - 2001


  • Adenovirus
  • Gene therapy
  • Prostate cancer
  • Radioiodine therapy
  • Sodium iodide symporter

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics


Dive into the research topics of 'In vivo sodium iodide symporter gene therapy of prostate cancer'. Together they form a unique fingerprint.

Cite this